MENU
SBIO
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

SBIO stock forecast, quote, news & analysis

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
a Summary for SBIO with price predictions
Nov 10, 2026

SBIO's RSI Oscillator climbs out of oversold territory

The RSI Oscillator for SBIO moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 29 of the 30 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on SBIO as a result. In 77 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.

The Moving Average Convergence Divergence (MACD) for SBIO just turned positive on October 20, 2026. Looking at past instances where SBIO's MACD turned positive, the stock continued to rise in 45 of 51 cases over the following month. The odds of a continued upward trend are 88%.

Following a +9.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where SBIO advanced for three days, in 277 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

SBIO broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for SBIO entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are BioCryst Pharmaceuticals (NASDAQ:BCRX), Sarepta Therapeutics (NASDAQ:SRPT), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

Market Cap

The average market capitalization across the ALPS Medical Breakthroughs ETF (SBIO) ETF is 2.08B. The market cap for tickers in the group ranges from 63.25M to 6.81B. ORKA holds the highest valuation in this group at 6.81B. The lowest valued company is TENX at 63.25M.

High and low price notable news

The average weekly price growth across all stocks in the ALPS Medical Breakthroughs ETF (SBIO) ETF was 47%. For the same ETF, the average monthly price growth was 100%, and the average quarterly price growth was 317%. VCEL experienced the highest price growth at 44%, while ZURA experienced the biggest fall at -65%.

Volume

The average weekly volume growth across all stocks in the ALPS Medical Breakthroughs ETF (SBIO) ETF was -3%. For the same stocks of the ETF, the average monthly volume growth was 19% and the average quarterly volume growth was -32%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 44
P/E Growth Rating: 41
Price Growth Rating: 58
SMR Rating: 93
Profit Risk Rating: 87
Seasonality Score: 5 (-100 ... +100)
SBIO's RSI Oscillator climbs out of oversold territory